Voorbeelden van het gebruik van Kaplan-meier in het Engels en hun vertalingen in het Nederlands
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Financial
-
Computer
-
Ecclesiastic
-
Official/political
-
Programming
Kaplan-Meier estimate, months a.
Duration of MaHR%; Kaplan-Meier Estimates.
Kaplan-Meier medians Everolimus: 4.90 months.
Duration of MaHR%; Kaplan-Meier Estimates.
The Kaplan-Meier curves for OS are shown in Figure 6.
Based on the Kaplan-Meier estimates, 95% 95% CI.
Kaplan-Meier medians Afinitor:
Figure 1: Kaplan-Meier curves of OS CA209017.
Kaplan-Meier curves for overall survival intent-to-treat population.
Figure 6: Kaplan-Meier curves of OS CA209057.
Kaplan-Meier curve for PFS for the ITT population is provided in Figure 1.
Figure 5 RECORD-1- Kaplan-Meier progression-free survival curves independent central review.
The Kaplan-Meier estimate of overall survival at 2 years was 91.2.
Figure 2: Kaplan-Meier curve of overall survival.
The Kaplan-Meier estimate for survival after 36-month follow-up is 68.
Figure 1 BOLERO-2 Kaplan-Meier progression-free survival curves investigator radiological review.
Figure 4 Kaplan-Meier curve of IRC-assessed progression-free survival in patients with follicular lymphoma.
Figure 3 RADIANT-4- Kaplan-Meier progression-free survival curves independent radiological review.
Figure 1 Kaplan-Meier estimates for primary recurrence-free survival endpoint ITT population.
Figure 1 Kaplan-Meier overall survival curve, IMPACT study.
Figure 4: Kaplan-Meier plot-overall survival ITT population.
Figure 2 Kaplan-Meier curve of overall survival from Stage 1a.
Figure 1- Kaplan-Meier curve of PFS in the pNET Phase 3 Study.
Figure 2 Kaplan-Meier estimates for overall survival ITT population.
Figure 2 Kaplan-Meier curves Updated OS analysis for Study MEK116513.
Figure 1: Kaplan-Meier estimate of time to major molecular response MMR.
Figure 1: Kaplan-Meier curve of overall survival intent-to-treat population.
Figure 1 Kaplan-Meier curves for overall survival intent-to-treat population.
Figure 3: Kaplan-Meier Analysis of OS Among Subjects with a RET M918T Mutation.
Figure 1 Kaplan-Meier overall survival curves for Study MEK115306 ITT population.